ENXTAM:PHARMBiotechs
Can Pharming Group’s (ENXTAM:PHARM) Joenja Push Redefine Its Rare Disease Investment Narrative?
Earlier this week, Pharming Group reported first-quarter 2026 revenues of US$72.45 million versus US$79.09 million a year earlier, while its net loss narrowed to US$5.21 million from US$14.72 million, alongside reaffirmed full-year revenue guidance and regulatory progress for Joenja in Japan and Europe.
At the same time, Pharming highlighted advancing clinical and real-world data for leniolisib in pediatric APDS and CVID, underlining how its rare disease pipeline and label-expansion efforts...